Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis Reports Trial Results For Cabozantinib in Combination With Immunotherapies to Treat Colorectal Cancer

01/19/2022 | 03:17pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about EXELIXIS, INC.
05/11TRANSCRIPT : Exelixis, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11..
CI
05/10TRANSCRIPT : Exelixis, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Exelixis Q1 Non-GAAP EPS, Revenue Higher; Reiterates 2022 Guidance
MT
05/10EXELIXIS : Q1 Earnings Snapshot
AQ
05/10EXELIXIS, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/10Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
BU
05/10Earnings Flash (EXEL) EXELIXIS Posts Q1 EPS $0.26, vs. Street Est of $0.23
MT
05/10Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $356M, vs. Street Est of $363.2M
MT
05/10Exelixis, Inc. Reports Earnings Results for the First Quarter Ended April 01, 2022
CI
05/10Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2022
CI
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2022 1 587 M - -
Net income 2022 291 M - -
Net cash 2022 1 276 M - -
P/E ratio 2022 22,6x
Yield 2022 -
Capitalization 6 498 M 6 498 M -
EV / Sales 2022 3,29x
EV / Sales 2023 2,73x
Nbr of Employees 954
Free-Float 97,7%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 20,26 $
Average target price 26,53 $
Spread / Average Target 31,0%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.10.83%6 429
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601